A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant.

Trial Profile

A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2014

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; Adjuvants
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Sponsors Novavax
  • Most Recent Events

    • 05 Feb 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 31 Jul 2013 Planned End Date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 17 Apr 2013 Phase I results reviewed at World Vaccine Congress and Expo, according to a Novovax media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top